MIP Discovery specializes in the design, development, and manufacture of nanoMIPs – synthetic affinity reagents that offer unique characteristics alongside excellent performance. The company is focused on developing a range of research-grade materials in the fields of drugs of abuse testing and cell and gene therapy processes.

MIP Discovery

International MIP Seminar 2021

Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required.

The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed.

MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.

Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.

As we settle into 2024 our CEO, Stephane Argivier takes a look back at what was accomplished in 2023 at MIP Discovery and shares our ambitions for 2024.


Our team will be attending #bioProcessUK from the 28th – 30th November in #Brighton. At MIP Discovery, we design and build synthetic affinity reagents, generating an alternative approach for detection, capture and purification of target molecules. Historically, MIPs have been imprinted to recognize small molecules, drugs, DNA, whole cells and viruses. They have been exemplified in ELISA, BLI, magnetic resins and chromatography applications. We are working towards generating synthetic affinity reagents to recognize and capture Endotoxins, residual PEI, VSV-G and AAV capsids. Book a meeting with our team if you would like to learn more, and partner with us on this exciting journey. https://lnkd.in/ehDkW5hg Gavin Allsop Stephane Argivier

We are heading to Brussels for ESGCT next week. If you are at the event and want to chat about your current challenges in viral analytics and purification, be sure to meet with a member of our team to explore new possibilities... #ESGCT2023 #purification #viralanalytics https://lnkd.in/ehDkW5hg

The MIP Discovery team are excited to be attending ESGCT from the 24th – 27th October in Brussels. We are continuing our exploration of the possibilities synthetic affinity reagents can bring to the Cell and Gene Therapy arena. If you would like to chat about new approaches to viral analytics, safety analytics and viral purification, please book a meeting with a member of our team! #ESGCT2023 https://lnkd.in/ehDkW5hg 


Metric
Company Name	MIP Discovery
Symbol
MSH ID	COM:MIPDISCOVERY
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	GB
Stage
Employee Count	33
Website	mipdiscovery.com
LinkedIn	mipdiscovery
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MIPDISCOVERY

MIP Discovery

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue